- The New Money
- Posts
- US Set To Reschedule Cannabis, Nunavut Uranium, and Methane Reduction For Carbon Credits
US Set To Reschedule Cannabis, Nunavut Uranium, and Methane Reduction For Carbon Credits
Uncovering the world’s most exciting early stage companies. Discover what’s next.
The United States Is Set To Reclassify Cannabis
The US Drug Enforcement Agency is poised to reclassify cannabis following the Federal Health and Human Services Department previously putting out an official recommendation to remove cannabis as a Schedule I drug due to its medical and therapeutic potential and its relatively high safety profile. And it immediately sent shockwaves through the public markets, with Canopy Growth (NASDAQ:CGC) shares up 78% on the day.
ATHA Energy (TSXV:SASK) has assembled one of the largest uranium exploration portfolios in the world. And now, they are getting ready to begin drilling for new sources of uranium supply at their Angilak Project located in Nunavut, Canada.
Methane Reduction Registers on American Carbon Registry
Zefiro Methane (CBOE:ZEFI) has registered their first methane reduction project on American Carbon Registry, which is one of the largest carbon credit programs globally. The new registration brings Zefiro closer to being able to monetize high quality carbon credits generated through reducing methane leaks at abandoned oil and gas wells.
The Sprint
The Stock Exchange of Hong Kong officially listed spot Bitcoin and Ethereum ETFs, trading over a combined $11 million in their first day.
Zipline completed their one millionth drone-powered delivery, covering over 70 million miles across four continents.
Pascal landed $2.5 million in funding from legendary Silicon Valley venture fund a16z to advance their lab grown diamond production ability.
Trending Now
New here? Join our community of 25,000+ individuals interested in uncovering the world’s most exciting early stage companies.
Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.